Z

Zevra Therapeutics Inc
NASDAQ:ZVRA

Watchlist Manager
Zevra Therapeutics Inc
NASDAQ:ZVRA
Watchlist
Price: 9.03 USD 4.27% Market Closed
Market Cap: 475.2m USD
Have any thoughts about
Zevra Therapeutics Inc?
Write Note

Zevra Therapeutics Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zevra Therapeutics Inc
Accounts Payable Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zevra Therapeutics Inc
NASDAQ:ZVRA
Accounts Payable
$20.5m
CAGR 3-Years
90%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accounts Payable
$9B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Payable
$3.5B
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
3%
Pfizer Inc
NYSE:PFE
Accounts Payable
$5.1B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Accounts Payable
$3.6B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accounts Payable
$2.9B
CAGR 3-Years
23%
CAGR 5-Years
21%
CAGR 10-Years
11%

See Also

What is Zevra Therapeutics Inc's Accounts Payable?
Accounts Payable
20.5m USD

Based on the financial report for Jun 30, 2024, Zevra Therapeutics Inc's Accounts Payable amounts to 20.5m USD.

What is Zevra Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
21%

Over the last year, the Accounts Payable growth was 95%. The average annual Accounts Payable growth rates for Zevra Therapeutics Inc have been 90% over the past three years , 21% over the past five years .

Back to Top